(Q42945647)

English

Serum prostate‐specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu

scientific article published on September 15, 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Serum prostate‐specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu (English)

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

author name string

Itsuhiro Takizawa

1

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Tsutomu Nishiyama

2

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Noboru Hara

3

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Etsuko Isahaya

4

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Tatsuhiko Hoshii

5

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Kota Takahashi

6

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20687212

17 June 2024

publication date

1 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

15 September 2010

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20687212

17 June 2024

full work available at URL

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fpros.21174

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.21174

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

70

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

1395-1401

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21174

21 January 2018

Management of complications of prostate cancer treatment

1

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer

2

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression

3

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy

4

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

The influence of androgen deprivation therapy on metabolism in patients with prostate cancer

6

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

Bone metabolic disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): impact of ADT on the growth hormone/insulin-like growth factor-1/parathyroid hormone axis

7

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

Decline of the red blood cell count in patients receiving androgen deprivation therapy for localized prostate cancer: impact of ADT on insulin-like growth factor-1 and erythropoiesis

8

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

Effectiveness of castration versus intravenous estrogen therapy in producing rapid endocrine control of metastatic cancer of the prostate

10

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

Endocrine treatment of prostate cancer

11

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making

12

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy

13

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

Long-term Survival Among Men With Conservatively Treated Localized Prostate Cancer

14

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy

16

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

Primary Gleason pattern as a predictor of disease progression in gleason score 7 prostate cancer: a multivariate analysis of 823 men treated with radical prostatectomy

17

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer

18

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score

19

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies

20

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

Testosterone replacement therapy and prostate cancer

21

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth

22

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

Biology of prostate-specific antigen

23

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

Is low serum free testosterone a marker for high grade prostate cancer?

24

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

High-grade prostate cancer is associated with low serum testosterone levels

25

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy

26

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer

27

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group

28

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men.

29

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

Influence of radical prostatectomy on serum hormone levels

30

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

Does presence of prostate cancer affect serum testosterone levels in clinically localized prostate cancer patients?

31

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

Association between prostate cancer and serum testosterone levels

32

1 reference

10.1002/PROS.21174

https://api.crossref.org/works/10.1002/PROS.21174

17 June 2024

Identifiers

10.1002/PROS.21174

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42945647&oldid=2228768883"